TTAC-0001 and pembrolizumab combination
Sponsors
PharmAbcine
Conditions
Recurrent GlioblastomaTriple Negative Breast Cancer
Phase 1
TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer
NCT03720431
Start: 2019-01-03End: 2022-10-26Updated: 2022-08-17
TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma
NCT03722342
Start: 2019-01-16End: 2022-09-30Updated: 2022-08-17